1-<2-(1,3-dioxolan-2-yl)ethyl>-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide | 110862-45-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-<2-(1,3-dioxolan-2-yl)ethyl>-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide
• 英文别名: 1-(2-[1,3]dioxolan-2-ylethyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide；1H-Pyrrole-3-carboxamide, 1-[2-(1,3-dioxolan-2-yl)ethyl]-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-；1-[2-(1,3-dioxolan-2-yl)ethyl]-5-(4-fluorophenyl)-N,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide
• CAS: 110862-45-8
• 化学式: C₃₁H₃₁FN₂O₃
• 分子量: 498.597
• InChiKey: XDOBANVOMNZYOO-UHFFFAOYSA-N

物化性质

• 熔点：
  161-163 °C
• 沸点：
  587.1±50.0 °C(Predicted)
• 密度：
  1.20±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  37
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  52.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-<2-(1,3-dioxolan-2-yl)ethyl>-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide 在 盐酸 、 正丁基锂 、 水 、 sodium hydride 、 对甲苯磺酸 作用下， 反应 26.0h， 生成 methyl 7-<2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-<(phenylamino)carbonyl>-1H-pyrrol-1-yl>-5-hydroxy-3-oxo-1-heptanoate
  参考文献：
  名称：

  Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus

  摘要：

  A series of trans-tetrahydro-4-hydroxy-6-[2-(2,3,4,5-substituted-1H-pyrrol-1-yl)ethyl]-2H-pyran-2-ones and their dihydroxy acids were prepared and tested for their ability to inhibit the enzyme HMG-CoA reductase in vitro. Inhibitory potency was found to increase substantially when substituents were introduced into positions three and four of the pyrrole ring. A systematic exploration of structure-activity relationships at these two positions led to the identification of a compound ((+)-33, (+)-(4R)-trans-2-(4-fluorophenyl)-5-(1-methylethyl)-N,3-diphenyl-1-[(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-4-carboxamide) with five times the inhibitory potency of the fungal metabolite compactin.

  DOI：

  10.1021/jm00105a056
• 作为产物：
  描述：

  2-(2-氨乙基)-1,3-二氧戊环 在 sodium hydroxide 、 乙酸酐 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 7.0h， 生成 1-<2-(1,3-dioxolan-2-yl)ethyl>-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1H-pyrrole-3-carboxamide
  参考文献：
  名称：

  Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus

  摘要：

  A series of trans-tetrahydro-4-hydroxy-6-[2-(2,3,4,5-substituted-1H-pyrrol-1-yl)ethyl]-2H-pyran-2-ones and their dihydroxy acids were prepared and tested for their ability to inhibit the enzyme HMG-CoA reductase in vitro. Inhibitory potency was found to increase substantially when substituents were introduced into positions three and four of the pyrrole ring. A systematic exploration of structure-activity relationships at these two positions led to the identification of a compound ((+)-33, (+)-(4R)-trans-2-(4-fluorophenyl)-5-(1-methylethyl)-N,3-diphenyl-1-[(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-4-carboxamide) with five times the inhibitory potency of the fungal metabolite compactin.

  DOI：

  10.1021/jm00105a056

文献信息

• Potassium Acetate-Catalyzed Double Decarboxylative Transannulation To Access Highly Functionalized Pyrroles
  作者：Jun-Kuan Li、Biying Zhou、Yu-Chen Tian、Chunman Jia、Xiao-Song Xue、Fa-Guang Zhang、Jun-An Ma

  DOI：10.1021/acs.orglett.0c03621

  日期：2020.12.18

  remodeling by utilizing CO2 moiety as traceless activating and directing groups in both reaction partners. The synthetic value is evidenced by the rapid preparation of a broad spectrum of highly functionalized 3-carbamoyl-4-aryl pyrroles in good to excellent yields with exclusive regio-control, including the important Atorvastatin core.

  有效构建通用吡咯药物核心的新合成策略的开发，尤其是在操作上简单且对环境无害的方式，仍然是一个艰巨而具有挑战性的目标。在这里，我们报告了易于获得的恶唑酮和异恶唑烷二酮之间的KOAc催化的双脱羧环过氧化物。这种转化代表了利用CO 2部分作为两个反应伙伴中无痕的活化和引导基团进行骨骼重塑的新方法。合成的价值可通过快速制备各种高官能度的3-氨基甲酰基-4-芳基吡咯，以良好的收率，并通过独家区域控制（包括重要的阿托伐他汀核心）来获得。
• PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN
  申请人：Cho Dong-Ock

  公开号：US20110112309A1

  公开（公告）日：2011-05-12

  The present invention relates to a preparation process useful in synthesis of atorvastatin, more particularly a process for preparing atorvastatin is effective in treating hyperlipemia, comprising protecting the dihydroxy group at C3 and C5 positions of the starting material cis-t-butyl-6-substituted-3,5-dihydroxy-hexanoate with trialkyl orthoformate, reducing the terminal nitro or cyano group to amine group, performing JV-alkylation by sequentially reacting with ethyl 4-fluorobenzene-2-haloacetate and isobutyryl chloride, cyclizing with JV,3-diphenylpropynamide, and performing deprotection and hydrolysis.

  本发明涉及一种在阿托伐他汀合成中有用的制备过程，更具体地，涉及一种制备阿托伐他汀的处理方法，用于治疗高脂血症，包括通过使用三烷基正甲酸酯保护起始物质顺丁基-6-取代-3,5-二羟基己酸酯的C3和C5位置的二羟基基团，将末端硝基或氰基还原为胺基团，通过依次与乙基4-氟苯基-2-卤代乙酸酯和异丁酰氯反应进行JV-烷基化，与JV，3-二苯基丙炔酰胺环化，并进行去保护和水解。
• Trans-6-[2-(3- or 4-Carboxamido-substituted pyrrol-1-yl)-alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0247633A1

  公开（公告）日：1987-12-02

  Certain trans-6-[2-(3- or 4-carboxamido-­substitutedpyrrol-1-yl)alkyl]-4-hydroxypyran-2-ones and the corresponding ring-opened acids derived therefrom which are potent inhibitors of the enzyme 3-hydroxy-3-­methylglutaryl-coenzyme A reductase (HMG CoA reductase) and are thus useful hypolipidemic or hypocholesterolemic agents. Pharmaceutical compositions containing such compounds, and a method of inhibiting the biosynthesis of cholesterol employing such pharmaceutical composi­tions are also disclosed.

  特定的trans-6-[2-(3-或4-羧酰胺基取代吡咯-1-基)烷基]-4-羟基吡喃-2-酮及其相应的开环酸衍生物是酶3-羟基-3-甲基戊二酰辅酶A还原酶（HMG CoA还原酶）的有效抑制剂，因此可用作降脂或降胆固醇药物。还公开了含有这些化合物的制药组合物，以及使用这些制药组合物抑制胆固醇生物合成的方法。
• [EN] STABLE ORAL CI-981 FORMULATION AND PROCESS OF PREPARING SAME<br/>[FR] FORMULATION CI-981, ORALE, STABLE ET SON PROCEDE DE PREPARATION
  申请人：WARNER-LAMBERT COMPANY

  公开号：WO1994016693A1

  公开（公告）日：1994-08-04

  (EN) An oral pharmaceutical composition is provided for treating hypercholesterolemia or hyperlipidemia containing an advantageous formulation for stabilizing the HMG-CoA coenzyme A inhibitor, CI-981 Hemi-Calcium, of formula (IA) with effective amounts of calcium carbonate. A method for preparing a CI-981 stabilizing composition is described.(FR) Une composition pharmaceutique orale est utilisée dans le traitement de l'hypercholestérolémie ou l'hyperlipidémie et contient une formulation avantageuse permettant de stabiliser l'inhibiteur A coenzymatique HMG-CoA, l'Hemi-Calcium CI-981, de la formule (IA) avec des quantités efficaces de carbonate de calcium. L'invention concerne également un procédé de préparation d'une composition stabilisante CI-981.

  提供一种口服药物组合物，用于治疗高胆固醇血症或高脂血症，其中包含一种优越的配方，用于稳定式(I-A)的HMG-CoA辅酶A抑制剂CI-981 Hemi-Calcium，并含有有效量的碳酸钙。还描述了一种制备CI-981稳定组合物的方法。
• (R-(R*R*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl-3-phenyl-4((phenylamino)-carbonyl)-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1061073A1

  公开（公告）日：2000-12-20

  [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-((1-methylethyl)-3-phenyl-4-[(phenylamino)-carbonyl)-1H-pyrrole-1-heptanoic acid or (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide; a process for their preparation and pharmaceutically acceptable salts thereof.

  [R-(R*,R*)]-2-(4-氟苯基)-β,δ-双羟基-5-((1-甲基乙基)-3-苯基-4-[(苯氨酰)基]-1H-吡咯-1-庚酸或(2R-trans)-5-(4-氟苯基)-2-(1-甲基乙基-N,4-二苯基-1-[2-(四氢-4-羟基-6-氧代-2H-吡喃-2-基)乙基]-1H-吡咯-3-羧酰胺；以及其制备方法和药学上可接受的盐。